Efficacy of bevacizumab in combination with irinotecan or oxaliplatin as 2nd and 3rd or later-line treatment in metastatic colorectal cancer (MCRC) patients

被引：0
|
作者：
Samalin, E.
Lievre, A.
Boyer-Gestin, C.
Mitry, E.
Senesse, P.
Lepere, C.
Bachet, J.
Vaillant, J.
Rougier, J.
Ychou, M.
机构：
[1] Ccentre Aurelle, Montpellier, France
[2] Hop Ambroise Pare, Boulogne Billancourt, France
来源：
ANNALS OF ONCOLOGY | 2007年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：VII30 / VII30
页数：1
相关论文
共 50 条
  • [21] 2nd line bevacizumab(BEV) continuation chemotherapy(Cx) beyond early progression for metastatic colorectal cancer(mCRC)
    Komoda, Masato
    Yamamoto, Shun
    Kawakami, Takeshi
    Mitani, Seiichiro
    Tsuji, Yasushi
    Izawa, Naoki
    Kawakami, Kentaro
    Yamamoto, Yoshiyuki
    Makiyama, Akitaka
    Yamazaki, Kentaro
    Masuishi, Toshiki
    Esaki, Taito
    Tsuda, Takashi
    Okuda, Hiroyuki
    Moriwaki, Toshikazu
    Boku, Narikazu
    ANNALS OF ONCOLOGY, 2019, 30 : 100 - 100
  • [22] First line treatment of metastatic colorectal cancer (MCRC) with the combination of capecitabine, irinotecan, and oxaliplatin (XELOXIRI): Preliminary results of a pilot study by the GONO group
    Burs, S.
    Masi, G.
    Loupakis, F.
    Antonuzzo, A.
    Tognarini, L.
    Sonaglio, C.
    Chiara, S.
    Pfanner, E.
    Brunetti, I
    Petrini, I
    Baldi, G.
    Barletta, M.
    Allegrini, G.
    Ricci, S.
    Falcone, A.
    ANNALS OF ONCOLOGY, 2007, 18 : VII27 - VII27
  • [23] Efficacy and safety of third-line or later-line targeted treatment for patients with metastatic colorectal cancer: a meta-analysis
    Xue, Wen-Hui
    Li, Xue-Wei
    Ding, Ya-Qian
    Wu, Na
    Pei, Bei-Bei
    Ma, Xiao-Yan
    Xie, Jun
    Yang, Wen-Hui
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [24] Phase II study to evaluate efficacy and safety of irinotecan, capecitabine, and bevacizumab in patients with metastatic colorectal cancer (mCRC)
    Garcia Alfonso, P.
    Chaves, M.
    Munoz Martin, A.
    Salud Salvia, A.
    Vilchez, R.
    Yuste, A.
    Gravalos Castro, C.
    Queralt Merino, B.
    Gonzalez Flores, E.
    Lopez Ladron, A.
    Losa, F.
    Oltra Ferrando, A.
    Gomez Reina, M. J.
    Campos, J. M.
    Aranda, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [25] PHASE II STUDY TO EVALUATE EFFICACY AND SAFETY OF IRINOTECAN, CAPECITABINE AND BEVACIZUMAB IN METASTATIC COLORECTAL CANCER (MCRC) PATIENTS
    Garcia Alfonso, Pilar
    Chaves, Manuel
    Munoz, Andres
    Salud, Antonieta
    Garcia-Giron, Carlos
    Gravalos, Cristina
    Massuti, Bartomeu
    Gonzalez-Flores, Encarnacion
    Queralt, Bernardo
    Lopez-Ladron, Amelia
    Losa, Ferran
    Oltra, Amparo
    Jose Gomez, Ma
    Manuel Campos, J.
    Aranda, Enrique
    ANNALS OF ONCOLOGY, 2012, 23 : 103 - 104
  • [26] Phase II study to evaluate efficacy and safety of irinotecan, capecitabine, and bevacizumab in metastatic colorectal cancer (mCRC) patients
    Garcia Alfonso, Pilar
    Chaves-Conde, Manuel
    Munoz, Andres
    Salud, Antonia
    Garcia-Giron, Carlos
    Gravalos Castro, Cristina
    Massuti, Bartomeu
    Gonzalez Flores, Encarnacion
    Queralt, Bernardo
    Lopez Ladron, Amelia
    Losa, Ferran
    Oltra Ferrando, Amparo
    Gomez Reina, Maria Jose
    Garcia-Carbonero, Rocio
    Garcia-Escobar, Ignacio
    Aranda, Enrique
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [27] Capetabine plus irinotecan (CAPIRI) as first line treatment for patients with metastatic colorectal cancer(MCRC)
    Laudani, A.
    Alu, M.
    Leonardi, V
    Savio, G.
    Pepe, A.
    Palmisano, V
    Targaglia, L.
    Porretto, C.
    Manuguerra, G.
    Calabria, C.
    Agostara, B.
    ANNALS OF ONCOLOGY, 2007, 18 : VII41 - VII41
  • [28] CAPECITABINE AND IRINOTECAN (CAPIRI) AS FIRST - LINE TREATMENT FOR PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC)
    Adda, B.
    Farida, S.
    ANNALS OF ONCOLOGY, 2009, 20 : 73 - 73
  • [29] Impact of the addition of bevacizumab, oxaliplatin or irinotecan to fluoropyrimidin in the first-line treatment of metastatic colorectal cancer in elderly patients.
    Landre, Thierry
    Aparicio, Thomas
    Ghebriou, Djamel
    Nicolas, Patrick
    Taleb, Cherifa
    Chouahnia, Kader
    Zelek, Laurent H.
    Des Guetz, Gaetan
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [30] CAPECITABINE AND IRINOTECAN (CAPIRI) AS FIRST -LINE TREATMENT FOR PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC)
    Bounedjar, A.
    Smail, F.
    ANNALS OF ONCOLOGY, 2010, 21 : 67 - 68
12345